dc.contributor.author |
Ribas i Fortuny, Judit |
dc.contributor.author |
Boix Torras, Jacint |
dc.contributor.author |
Meijer, Laurent |
dc.date |
2015-03-23T18:37:36Z |
dc.date |
2015-03-23T18:37:36Z |
dc.date |
2006 |
dc.date |
2015-03-23T18:37:36Z |
dc.identifier |
0014-4827 |
dc.identifier |
http://hdl.handle.net/10459.1/48093 |
dc.identifier |
https://doi.org/10.1016/j.yexcr.2006.04.021 |
dc.identifier.uri |
http://hdl.handle.net/10459.1/48093 |
dc.description |
In this study, we have analyzed the consequences, on several neuroblastoma cell lines, of combined treatments with (R)-roscovitine (CYC202, Seliciclib), a CDK inhibitory drug, and nutlin-3, a p53 activating drug. Both compounds were found to synergize, causing significant levels of apoptosis in cultured cells when combined at sublethal concentrations. In SH-SY5Y cells, Bcl-XL protein overexpression protected from apoptosis induced by either nutlin-3 alone or the (R)-roscovitine plus nutlin-3 association but failed to prevent apoptosis triggered by (R)-roscovitine alone. Moreover, Western blot studies showed that (R)-roscovitine increased nutlin-3-mediated p53 stabilization. Therefore, we conclude the contribution of (R)-roscovitine to the synergism is basically the sensitization of SH-SY5Y cells to the action of nutlin-3 on p53. The relevance of this pharmacological synergism with respect to the treatment of neuroblastoma is discussed. |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
Elsevier |
dc.relation |
Versió postprint del document publicat a: https://doi.org/10.1016/j.yexcr.2006.04.021 |
dc.relation |
Experimental Cell Research, 2006, vol. 312, num. 12, p. 2394-2400 |
dc.rights |
(c) Elsevier, 2006 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Apoptosis |
dc.subject |
Cell Cycle |
dc.subject |
Nutlins |
dc.subject |
p53 |
dc.subject |
Roscovitine |
dc.subject |
Apoptosi |
dc.subject |
Càncer |
dc.subject |
Cicle cel·lular |
dc.subject |
Apoptosis |
dc.subject |
Cancer |
dc.subject |
Cell cycle |
dc.title |
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/acceptedVersion |